Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial.

Name: Kaimen Rigor review — Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial.
Item: Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial.
Rating: 100
Author: Alpha1

Usmani SZ, Facon T, Hungria V, Bahlis NJ, Venner CP, Braunstein M, Pour L, Martí JM, Basu S, Cohen YC, Matsumoto M, Suzuki K, Hulin C, Grosicki S, Legiec W, Beksac M, Maiolino A, Takamatsu H, Perrot A, Turgut M, Ahmadi T, Liu W, Wang J, Chastain K, Vermeulen J, Krevvata M, Lopez-Masi L, Carey J, Rowe M, Carson R, Zweegman S

Paper source

Read full text (PMC)

Embed this Rigor badge

Kaimen Rigor review — 4★ (Strong), 0 critical, 0 high issues for “Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial.”

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Read alongside

Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial.

Read full text (PMC)

DOI

10.1038/s41591-024-03485-7

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/310f825c-fb7d-4cf2-b286-5b9a6a4fcd3d" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/310f825c-fb7d-4cf2-b286-5b9a6a4fcd3d/badge" alt="Kaimen Rigor review — 4★ (Strong), 0 critical, 0 high issues for “Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

75e2284804475f4f9caa68557f18e501f609a86222dc48cc390ae4657dc9342a

Verify via API

Issued Aug 15, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Alpha¹ by Kaimen

Fetching the latest research

Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial.

Paper source

Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial.

Read full text (PMC)

Embed this Rigor badge

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Kaimen Rigor review

Kaimen Rigor reviewed

4 / 5

Strong — minor issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary endpoint is minimal residual disease (MRD) negativity, a surrogate biomarker, not a hard clinical outcome. Although the paper reports a significant improvement in progression-free survival (PFS), the primary efficacy claim is based on MRD negativity. The paper does not provide evidence of target engagement at the tested dose (e.g., PK/PD data) nor does it cite validated evidence linking MRD negativity to clinical outcomes in this context, despite mentioning its use as an accelerated approval endpoint.
“The primary endpoint was overall minimal residual disease (MRD)-negativity rate at 10 − 5 by next-generation sequencing.”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The primary effect size is the difference in MRD-negativity rates: 60.9% with D-VRd versus 39.4% with VRd (odds ratio 2.37). While statistically significant, the clinical meaningfulness of this surrogate improvement is not anchored to a minimal clinically important difference or a direct patient-centered outcome. The PFS improvement (HR 0.57) is reported but is a secondary endpoint and not the primary basis for the efficacy claim.
“the MRD-negativity rate was 60.9% with D-VRd versus 39.4% with VRd (odds ratio, 2.37; 95% confidence interval (CI), 1.58–3.55; P < 0.0001)”
Find in source

Findings by category

01ArithmeticNone found 302OverreachOverstated conclusions 03AuthenticityNone found 04DisclosureNone found 05AvailabilityNone found 06Copyedit3 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and transparently reported phase 3 randomized clinical trial. The manuscript demonstrates strong scientific premise, rigorous design, comprehensive reporting of biological variables, ethical approvals, key resources, statistical methods, data availability, and transparency. Only minor reporting gaps (e.g., explicit CONSORT statement) and copyedit issues were identified.

Both reviewers independently scored all eight dimensions and agreed on 'pass' for each. The study type is interventional (randomized controlled trial). The statistics verification covered only 2 tests (limited to those with test statistics/df or effect estimates with CIs); other reported statistics were not machine-verified. The citation check found no retracted or unresolved references. The reproducibility check confirmed both data links are live.

Numerical inconsistencies

None found

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Checked — nothing surfaced.

Recomputed 2 tests: 2 consistent, 0 inconsistent; 2 via agent-written checks.

Overstated conclusions

3 findings · worst high

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

7 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

None found

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Checked — nothing surfaced.

Reporting gaps

None found

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Checked — nothing surfaced.

Eight Dimensions8 pass

The introduction cites multiple prior studies establishing the efficacy of daratumumab-based regimens and VRd as standard of care, and the rationale for the CEPHEUS trial is clearly stated. The paper acknowledges limitations of prior work, such as the need for quadruplet therapy in transplant-ineligible patients and the context of the COVID-19 pandemic.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The paper establishes a strong scientific premise by citing prior phase 3 trials (MAIA, PERSEUS, SWOG S0777) and provides a clear rationale for evaluating D-VRd in this patient population.

Evidence

“Frontline daratumumab-based triplet and quadruplet standard-of-care regimens have demonstrated improved survival outcomes.”

Main, paragraph 1Find in source

“The phase 3 CEPHEUS study evaluated quadruplet D-VRd versus VRd alone in patients with NDMM who were transplant ineligible or for whom transplant was not planned as the initial therapy (transplant deferred).”

Main, paragraph 1Find in source

“Sensitivity analyses provided stronger evidence of the treatment effect of D-VRd on overall survival after adjusting for the impact of COVID-19.”

Discussion ¶1Find in source

PASSReviewer 2· 95% conf

The paper establishes a strong scientific premise by citing prior phase 3 trials (MAIA, PERSEUS, ALCYONE, SWOG S0777) and clearly rationalizes the study rationale.

Evidence

“Frontline daratumumab-based triplet and quadruplet standard-of-care regimens have demonstrated improved survival outcomes. For transplant-ineligible patients, significant progression-free survival (PFS) benefit was observed with frontline daratumumab plus lenalidomide and dexamethasone (D-Rd) triplet therapy versus lenalidomide and dexamethasone (Rd) alone in the phase 3 MAIA study”

Introduction ¶1Find in source

Introduction ¶3Find in source

paraphrase[Introduction]

“Paraphrase: The introduction notes that D-Rd is standard for transplant-ineligible patients but does not explicitly discuss limitations of prior studies, instead focusing on the rationale for adding bortezomib.”

Randomization was performed using randomly permuted blocks via an interactive web-response system, stratified by ISS stage and age/transplant eligibility. The sponsor remained blinded at interim analyses. A power analysis was conducted to detect a 15% difference in MRD-negativity rate. Inclusion/exclusion criteria are detailed. Outlier handling is addressed through the pre-specified analysis population (ITT) and sensitivity analyses. Controls are inherent in the randomized comparator arm. Independent replication is not applicable for a single pivotal trial.

Sub-criteria

controlsADEQUATE

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The study design is rigorous with clear randomization, stratification, blinding of the sponsor, a priori power analysis, and pre-specified inclusion/exclusion criteria.

Evidence

“Patients were randomly assigned (1:1) to D-VRd or VRd by randomly permuted blocks using an interactive web-response system.”

MethodsFind in source

“At both the primary MRD analysis and interim PFS analysis, the Independent Data Monitoring Committee recommended continuing the study unmodified and the sponsor remained blinded.”

Statistical analysisFind in source

“We estimated that a sample size of 360 patients (180 in each arm) was needed to achieve 80% power to detect a 15% treatment difference in overall MRD-negativity rate at a two-sided alpha of 0.05.”

Statistical analysisFind in source

PASSReviewer 2· 95% conf

The trial design is rigorous with clear randomization, stratification, blinding of sponsor to interim analyses, and a pre-specified sample size calculation.

Evidence

“Patients were randomly assigned (1:1) to D-VRd or VRd by randomly permuted blocks using an interactive web-response system.”

MethodsFind in source

Statistical analysisFind in source

“At both the primary MRD analysis and interim PFS analysis, the Independent Data Monitoring Committee recommended continuing the study unmodified and the sponsor remained blinded.”

Statistical analysisFind in source

The paper reports sex, age, race, ECOG performance status, frailty score, ISS stage, and cytogenetic risk in Table 1. Since both sexes are enrolled, sex_justified is not applicable. Age, weight, and health status are reported via ECOG and frailty scores. Species/strain and housing conditions are not applicable for a human trial.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Demographic and clinical characteristics are comprehensively reported, including age, sex, race, ECOG status, ISS stage, and cytogenetic risk.

Evidence

“Male sex, no. (%) b | 87 (44.2) | 111 (56.1)”

Table 1Find in source

“The median patient age was 70 years (range 31–80 years); 28.1% had International Staging System (ISS) stage III disease, and 13.2% had high cytogenetic risk (t(4;14), t(14;16) or del(17p)).”

ResultsFind in source

PASSReviewer 2· 95% conf

Demographic and baseline characteristics are thoroughly reported, including age, sex, race, ECOG status, ISS stage, and cytogenetic risk.

Evidence

“Male sex, no. (%) b | 87 (44.2) | 111 (56.1)”

Table 1Find in source

“Median (range) (years) | 70 (42–79) | 70 (31–80)”

Table 1Find in source

paraphrase[Table 1]

“Race, no. (%) b | White | 162 (82.2) | 156 (78.8)”

The paper states that an independent ethics committee or institutional review board approved the protocol at each site, and all patients provided written informed consent. Regulatory compliance with ICH-GCP and the Declaration of Helsinki is stated.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approvals and informed consent are clearly documented, with a named ethics committee approval and written informed consent from all patients.

Evidence

“An independent ethics committee or institutional review board approved the protocol at each site.”

MethodsFind in source

“All patients provided written informed consent.”

MethodsFind in source

“The study was conducted in accordance with the International Conference on Harmonisation Good Clinical Practice guidelines, the principles originating from the Declaration of Helsinki and study site-specific regulations.”

MethodsFind in source

PASSReviewer 2· 95% conf

Ethics approval, informed consent, and regulatory compliance are clearly reported.

Evidence

“An independent ethics committee or institutional review board approved the protocol at each site.”

MethodsFind in source

“All patients provided written informed consent.”

MethodsFind in source

The trial uses a drug combination, so the bench criteria (antibodies, cell lines, mycoplasma, organisms) are not applicable. The investigational products are adequately identified with doses and schedules. The MRD assay (clonoSEQ) is identified. Statistical software (SAS 9.4) is identified.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The investigational products (daratumumab, bortezomib, lenalidomide, dexamethasone) are identified with dosing and formulation details, and the statistical software is identified.

Evidence

“All patients received eight 21-day cycles of VRd, consisting of subcutaneous bortezomib (1.3 mg m −2 on days 1, 4, 8 and 11), oral lenalidomide (25 mg on days 1–14) and oral or intravenous dexamethasone (20 mg on days 1, 2, 4, 5, 8, 9, 11 and 12 (days 1, 4, 8 and 11 if aged >75 years or body mass index <18.5 kg m −2 ))”

MethodsFind in source

“All statistical analyses were performed using SAS Software 9.4 (TS1M6 MBCS3170).”

Data availabilityFind in source

PASSReviewer 2· 95% conf

The investigational products (daratumumab, bortezomib, lenalidomide, dexamethasone) are identified with dosing and formulation details, and the MRD assay (clonoSEQ) is specified.

Evidence

MethodsFind in source

“MRD was evaluated via next-generation sequencing using the clonoSEQ assay”

MethodsFind in source

“All statistical analyses were performed using SAS Software 9.4 (TS1M6 MBCS3170).”

Data availabilityFind in source

The paper names the statistical tests (Cochran–Mantel–Haenszel, log-rank, Cox regression) and reports exact p-values (e.g., P < 0.0001) and effect sizes with 95% CIs. Assumptions are handled by design (stratified tests, hierarchical testing). Data presentation includes Kaplan-Meier curves and forest plots. Mathematical plausibility is not applicable for large-N continuous outcomes.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Statistical methods are appropriate and well-described, with named tests, exact p-values, effect sizes with CIs, and software identified.

Evidence

“Overall MRD-negativity rates and rates of ≥CR were compared between groups using the stratified Cochran–Mantel–Haenszel test.”

Statistical analysisFind in source

paraphrase[Abstract]

“P < 0.0001”

“odds ratio, 2.37; 95% confidence interval (CI), 1.58–3.55”

AbstractFind in source

PASSReviewer 2· 95% conf

Statistical methods are well-described, with named tests, exact p-values, effect sizes with CIs, and appropriate data presentation for a clinical trial.

Evidence

“Overall MRD-negativity rates and rates of ≥CR were compared between groups using the stratified Cochran–Mantel–Haenszel test. Time-to-event endpoints, including PFS, were compared between groups using a stratified log(rank test).”

Statistical analysisFind in source

paraphrase[Abstract]

“P < 0.0001”

“odds ratio, 2.37; 95% confidence interval (CI), 1.58–3.55”

AbstractFind in source

The data availability statement provides a concrete route for data access through the YODA Project, which is a managed-access platform. Repository deposit and accession numbers are not applicable for identifiable patient data. Code sharing is not applicable as no bespoke code was written; the study used electronic Case Report Forms and SAS.

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Data availability is adequately described with a concrete access route via the YODA project, and code availability is addressed.

Evidence

“requests for access to the study data can be submitted through the Yale Open Data Access (YODA) Project site at http://yoda.yale.edu”

Data availabilityFind in source

PASSReviewer 2· 95% conf

Data availability is clearly stated with a concrete access route via the YODA project, and code availability is addressed (though no custom code is shared).

Evidence

“The data sharing policy of Johnson & Johnson is available at https://innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency . As noted on this site, requests for access to the study data can be submitted through the Yale Open Data Access (YODA) Project site at http://yoda.yale.edu .”

Data availabilityFind in source

The trial is registered (NCT03652064). Methods are detailed enough for replication. Limitations are discussed, including underrepresentation of Black patients and COVID-19 impact. Conclusions are proportional to the evidence. Funding and competing interests are disclosed.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineINADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The manuscript is transparent with detailed methods, trial registration, limitations discussion, proportional conclusions, and funding/COI statements.

Evidence

“ClinicalTrials.gov registration: NCT03652064”

AbstractFind in source

“A potential limitation of the CEPHEUS study is that patients who are Black or African American represented 4.8% of the total study population, which in some countries may be an underrepresentation.”

Discussion ¶8Find in source

“The present study was sponsored by Johnson & Johnson.”

AcknowledgementsFind in source

PASSReviewer 2· 95% conf

The manuscript is transparent with detailed methods, trial registration, discussion of limitations, proportional conclusions, and funding/COI statements.

Evidence

“ClinicalTrials.gov registration: NCT03652064”

AbstractFind in source

Discussion ¶8Find in source

“The present study was sponsored by Johnson & Johnson.”

AcknowledgementsFind in source

Registered (1 ID: ClinicalTrials.gov). Reporting guideline cited: CONSORT.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 29 references by DOI: 1 verified — 28 no DOI (shown, not verified).

2 data/code links checked; 2 live.

Copyediting

3 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 3 minor suggestions below.

3 copyedit issues flagged: mostly typo, consistency, grammar.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is robust and well-reported. An informed reader should weigh the open-label design and the underrepresentation of Black patients as limitations, but these are adequately discussed. No erratum or correction appears warranted based on the checks performed; the minor reporting gaps (explicit CONSORT statement, data access timeframe) are worth noting but do not undermine the conclusions.

1.
MEDIUMreporting
In the Methods or a dedicated section, explicitly state adherence to the CONSORT reporting guideline for randomized trials, including the version used.
The paper currently does not mention a reporting guideline, which is a standard expectation for clinical trials and would strengthen transparency.
2.
MEDIUMdata code
In the Data Availability section, clarify the timeframe and conditions for data access requests via the YODA Project.
The current statement lacks specific conditions or timelines, which would help readers understand the access process.
3.
MEDIUMreporting
In the Discussion, explicitly acknowledge the open-label design as a limitation and discuss potential bias from lack of blinding.
Open-label trials are susceptible to bias, and explicitly acknowledging this preempts concerns and improves balanced reporting.
4.
MEDIUMreporting
In the Discussion, expand the statement on generalizability to address underrepresentation of Black/African American patients and other minorities.
The current brief mention may not fully address the implications of limited diversity for the applicability of the findings.
5.
LOWcopyedit
In the Abstract, change 'Some 395 patients' to 'A total of 395 patients'.
The original phrasing is informal and less precise for a scientific manuscript.
6.
LOWcopyedit
In Results, Patients and treatment, rephrase '197 and 198 assigned to D-VRd and VRd, respectively' to '197 assigned to D-VRd and 198 to VRd'.
The suggested phrasing is clearer and avoids potential confusion.
7.
LOWcopyedit
In the Discussion, correct the grammar: 'the ultimate decision probably based on' to 'the ultimate decision is probably based on'.
The original sentence is missing a verb, which is a grammatical error.

Full text (51,662 chars)Analyzed: Aug 15, 2026

Start the discussion on JRNLClub

Community discussion on jrnlclub.com

Read alongside

Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial.

Read full text (PMC)

DOI

10.1038/s41591-024-03485-7

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/310f825c-fb7d-4cf2-b286-5b9a6a4fcd3d" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/310f825c-fb7d-4cf2-b286-5b9a6a4fcd3d/badge" alt="Kaimen Rigor review — 4★ (Strong), 0 critical, 0 high issues for “Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

75e2284804475f4f9caa68557f18e501f609a86222dc48cc390ae4657dc9342a

Verify via API

Issued Aug 15, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Kaimen Rigor review

Kaimen Rigor reviewed

4 / 5

Strong — minor issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary endpoint is minimal residual disease (MRD) negativity, a surrogate biomarker, not a hard clinical outcome. Although the paper reports a significant improvement in progression-free survival (PFS), the primary efficacy claim is based on MRD negativity. The paper does not provide evidence of target engagement at the tested dose (e.g., PK/PD data) nor does it cite validated evidence linking MRD negativity to clinical outcomes in this context, despite mentioning its use as an accelerated approval endpoint.
“The primary endpoint was overall minimal residual disease (MRD)-negativity rate at 10 − 5 by next-generation sequencing.”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The primary effect size is the difference in MRD-negativity rates: 60.9% with D-VRd versus 39.4% with VRd (odds ratio 2.37). While statistically significant, the clinical meaningfulness of this surrogate improvement is not anchored to a minimal clinically important difference or a direct patient-centered outcome. The PFS improvement (HR 0.57) is reported but is a secondary endpoint and not the primary basis for the efficacy claim.
“the MRD-negativity rate was 60.9% with D-VRd versus 39.4% with VRd (odds ratio, 2.37; 95% confidence interval (CI), 1.58–3.55; P < 0.0001)”
Find in source

Findings by category

01ArithmeticNone found 302OverreachOverstated conclusions 03AuthenticityNone found 04DisclosureNone found 05AvailabilityNone found 06Copyedit3 minor suggestions

Numerical inconsistencies

None found

Checked — nothing surfaced.

Recomputed 2 tests: 2 consistent, 0 inconsistent; 2 via agent-written checks.

Overstated conclusions

3 findings · worst high

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

7 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

None found

Checked — nothing surfaced.

Reporting gaps

None found

Checked — nothing surfaced.

Eight Dimensions8 pass

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The paper establishes a strong scientific premise by citing prior phase 3 trials (MAIA, PERSEUS, SWOG S0777) and provides a clear rationale for evaluating D-VRd in this patient population.

Evidence

“Frontline daratumumab-based triplet and quadruplet standard-of-care regimens have demonstrated improved survival outcomes.”

Main, paragraph 1Find in source

“Sensitivity analyses provided stronger evidence of the treatment effect of D-VRd on overall survival after adjusting for the impact of COVID-19.”

Discussion ¶1Find in source

PASSReviewer 2· 95% conf

The paper establishes a strong scientific premise by citing prior phase 3 trials (MAIA, PERSEUS, ALCYONE, SWOG S0777) and clearly rationalizes the study rationale.

Evidence

Introduction ¶1Find in source

Introduction ¶3Find in source

paraphrase[Introduction]

Sub-criteria

controlsADEQUATE

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The study design is rigorous with clear randomization, stratification, blinding of the sponsor, a priori power analysis, and pre-specified inclusion/exclusion criteria.

Evidence

“Patients were randomly assigned (1:1) to D-VRd or VRd by randomly permuted blocks using an interactive web-response system.”

MethodsFind in source

“At both the primary MRD analysis and interim PFS analysis, the Independent Data Monitoring Committee recommended continuing the study unmodified and the sponsor remained blinded.”

Statistical analysisFind in source

PASSReviewer 2· 95% conf

The trial design is rigorous with clear randomization, stratification, blinding of sponsor to interim analyses, and a pre-specified sample size calculation.

Evidence

“Patients were randomly assigned (1:1) to D-VRd or VRd by randomly permuted blocks using an interactive web-response system.”

MethodsFind in source

Statistical analysisFind in source

“At both the primary MRD analysis and interim PFS analysis, the Independent Data Monitoring Committee recommended continuing the study unmodified and the sponsor remained blinded.”

Statistical analysisFind in source

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Demographic and clinical characteristics are comprehensively reported, including age, sex, race, ECOG status, ISS stage, and cytogenetic risk.

Evidence

“Male sex, no. (%) b | 87 (44.2) | 111 (56.1)”

Table 1Find in source

“The median patient age was 70 years (range 31–80 years); 28.1% had International Staging System (ISS) stage III disease, and 13.2% had high cytogenetic risk (t(4;14), t(14;16) or del(17p)).”

ResultsFind in source

PASSReviewer 2· 95% conf

Demographic and baseline characteristics are thoroughly reported, including age, sex, race, ECOG status, ISS stage, and cytogenetic risk.

Evidence

“Male sex, no. (%) b | 87 (44.2) | 111 (56.1)”

Table 1Find in source

“Median (range) (years) | 70 (42–79) | 70 (31–80)”

Table 1Find in source

paraphrase[Table 1]

“Race, no. (%) b | White | 162 (82.2) | 156 (78.8)”

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approvals and informed consent are clearly documented, with a named ethics committee approval and written informed consent from all patients.

Evidence

“An independent ethics committee or institutional review board approved the protocol at each site.”

MethodsFind in source

“All patients provided written informed consent.”

MethodsFind in source

PASSReviewer 2· 95% conf

Ethics approval, informed consent, and regulatory compliance are clearly reported.

Evidence

“An independent ethics committee or institutional review board approved the protocol at each site.”

MethodsFind in source

“All patients provided written informed consent.”

MethodsFind in source

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The investigational products (daratumumab, bortezomib, lenalidomide, dexamethasone) are identified with dosing and formulation details, and the statistical software is identified.

Evidence

MethodsFind in source

“All statistical analyses were performed using SAS Software 9.4 (TS1M6 MBCS3170).”

Data availabilityFind in source

PASSReviewer 2· 95% conf

The investigational products (daratumumab, bortezomib, lenalidomide, dexamethasone) are identified with dosing and formulation details, and the MRD assay (clonoSEQ) is specified.

Evidence

MethodsFind in source

“MRD was evaluated via next-generation sequencing using the clonoSEQ assay”

MethodsFind in source

“All statistical analyses were performed using SAS Software 9.4 (TS1M6 MBCS3170).”

Data availabilityFind in source

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Statistical methods are appropriate and well-described, with named tests, exact p-values, effect sizes with CIs, and software identified.

Evidence

“Overall MRD-negativity rates and rates of ≥CR were compared between groups using the stratified Cochran–Mantel–Haenszel test.”

Statistical analysisFind in source

paraphrase[Abstract]

“P < 0.0001”

“odds ratio, 2.37; 95% confidence interval (CI), 1.58–3.55”

AbstractFind in source

PASSReviewer 2· 95% conf

Statistical methods are well-described, with named tests, exact p-values, effect sizes with CIs, and appropriate data presentation for a clinical trial.

Evidence

Statistical analysisFind in source

paraphrase[Abstract]

“P < 0.0001”

“odds ratio, 2.37; 95% confidence interval (CI), 1.58–3.55”

AbstractFind in source

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Data availability is adequately described with a concrete access route via the YODA project, and code availability is addressed.

Evidence

“requests for access to the study data can be submitted through the Yale Open Data Access (YODA) Project site at http://yoda.yale.edu”

Data availabilityFind in source

PASSReviewer 2· 95% conf

Data availability is clearly stated with a concrete access route via the YODA project, and code availability is addressed (though no custom code is shared).

Evidence

Data availabilityFind in source

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineINADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The manuscript is transparent with detailed methods, trial registration, limitations discussion, proportional conclusions, and funding/COI statements.

Evidence

“ClinicalTrials.gov registration: NCT03652064”

AbstractFind in source

Discussion ¶8Find in source

“The present study was sponsored by Johnson & Johnson.”

AcknowledgementsFind in source

PASSReviewer 2· 95% conf

The manuscript is transparent with detailed methods, trial registration, discussion of limitations, proportional conclusions, and funding/COI statements.

Evidence

“ClinicalTrials.gov registration: NCT03652064”

AbstractFind in source

Discussion ¶8Find in source

“The present study was sponsored by Johnson & Johnson.”

AcknowledgementsFind in source

Registered (1 ID: ClinicalTrials.gov). Reporting guideline cited: CONSORT.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 29 references by DOI: 1 verified — 28 no DOI (shown, not verified).

2 data/code links checked; 2 live.

Copyediting

3 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 3 minor suggestions below.

3 copyedit issues flagged: mostly typo, consistency, grammar.

Kaimen Rigor Action ItemsFinal pass before journal submission

1.
MEDIUMreporting
In the Methods or a dedicated section, explicitly state adherence to the CONSORT reporting guideline for randomized trials, including the version used.
The paper currently does not mention a reporting guideline, which is a standard expectation for clinical trials and would strengthen transparency.
2.
MEDIUMdata code
In the Data Availability section, clarify the timeframe and conditions for data access requests via the YODA Project.
The current statement lacks specific conditions or timelines, which would help readers understand the access process.
3.
MEDIUMreporting
In the Discussion, explicitly acknowledge the open-label design as a limitation and discuss potential bias from lack of blinding.
Open-label trials are susceptible to bias, and explicitly acknowledging this preempts concerns and improves balanced reporting.
4.
MEDIUMreporting
In the Discussion, expand the statement on generalizability to address underrepresentation of Black/African American patients and other minorities.
The current brief mention may not fully address the implications of limited diversity for the applicability of the findings.
5.
LOWcopyedit
In the Abstract, change 'Some 395 patients' to 'A total of 395 patients'.
The original phrasing is informal and less precise for a scientific manuscript.
6.
LOWcopyedit
In Results, Patients and treatment, rephrase '197 and 198 assigned to D-VRd and VRd, respectively' to '197 assigned to D-VRd and 198 to VRd'.
The suggested phrasing is clearer and avoids potential confusion.
7.
LOWcopyedit
In the Discussion, correct the grammar: 'the ultimate decision probably based on' to 'the ultimate decision is probably based on'.
The original sentence is missing a verb, which is a grammatical error.

Full text (51,662 chars)Analyzed: Aug 15, 2026